Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease

Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Simon Lam, Hong Yang, Ebru Coskun, Ezgi İdil, Rahim Nogaylar, Ahmet Hacımuftuoglu, Muhammad Arif, Saeed Shoaie, Cheng Zhang, Jens Nielsen, Hasan Turkez, Jan Borén, Mathias Uhlén, Adil Mardinoglu
doi: https://doi.org/10.1101/2021.07.28.21261293
Burak Yulug
1Department of Neurology and Neuroscience, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ozlem Altay
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiangyu Li
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lutfu Hanoglu
3Department of Neurology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seyda Cankaya
1Department of Neurology and Neuroscience, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Lam
4Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Yang
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ebru Coskun
3Department of Neurology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ezgi İdil
1Department of Neurology and Neuroscience, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rahim Nogaylar
1Department of Neurology and Neuroscience, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ahmet Hacımuftuoglu
5Department of Medical Pharmacology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad Arif
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saeed Shoaie
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
4Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Zhang
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
6School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Nielsen
7Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hasan Turkez
8Department of Medical Biology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Borén
9Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Uhlén
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adilm@scilifelab.se mathias.uhlen@scilifelab.se
Adil Mardinoglu
2Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm, Sweden
4Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King’s College London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: adilm@scilifelab.se mathias.uhlen@scilifelab.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

The neuropathologic hallmarks of Parkinson’s disease (PD) are associated with mitochondrial dysfunction and metabolic abnormalities. We have reported that the Combined Metabolic Activators (CMA), consisting of L-serine, nicotinamide riboside, N-acetyl-L-cysteine, and L-carnitine tartrate can be used in treating metabolic abnormalities. These metabolic activators are the precursors of nicotinamide adenine dinucleotide (NAD+) and glutathione (GSH) and used in activation of mitochondrial and global metabolism. We have performed a placebo-controlled, phase-2 study in Alzheimer’s disease (AD) patients and reported that the cognitive functions in AD patients is significantly improved 29% in the CMA group whereas it is improved only 14% in the placebo group after 84 days of CMA administration. Here, we designed a randomized, double-blinded, placebo-controlled, phase-2 study in PD patients with CMA administration. We found that the cognitive functions in PD patients is significantly improved 21% in the CMA group, whereas it is improved only 11% in the placebo group after 84 days of CMA administration. We also found that the administration of CMA did not affect motor functions in PD patients. We performed a comprehensive multi-omics analysis of plasma proteins and metabolites, and revealed the molecular mechanism associated with the treatment of the patients. In conclusion, our results show that treating PD patients with CMAs leads to enhanced cognitive function, as recently reported in AD patients.

Competing Interest Statement

AM, JB and MU are the founder and shareholders of ScandiBio Therapeutics. The other authors declare no competing interests.

Clinical Trial

NCT04044131

Funding Statement

This work was financially supported by ScandiBio Therapeutics and Knut and Alice Wallenberg Foundation. The authors would like to thank Metabolon Inc. (Durham, USA) for generating metabolomics data and ChromaDex Inc. (Irvine, CA, USA) for providing NR. AM and HY acknowledge support from the PoLiMeR Innovative Training Network (Marie Sklodowska-Curie Grant Agreement No. 812616), which received funding from the European Union's Horizon 2020 research and innovation programme.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the ethics committee of Istanbul Medipol University, Istanbul, Turkey

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Emails: burakyulug{at}gmail.com; havva.altay{at}scilifelab.se; xiangyu.li{at}scilifelab.se; lhanoglu{at}kure.com.tr; cankayaseyda{at}hotmail.com; simon.1.lam{at}kcl.ac.uk; hong.yang{at}scilifelab.se; ebrucosskun{at}gmail.com; ezgi.idil92{at}gmail.com; ngylrrhm{at}gmail.com; ahmeth{at}atauni.edu.tr; muhammad.arif{at}scilifelab.se; saeed.shoaie{at}scilifelab.se; cheng.zhang{at}scilifelab.se; nielsenj{at}chalmers.se; hasanturkez{at}yahoo.com; Jan.Boren{at}wlab.gu.se; mathias.uhlen{at}scilifelab.se; adilm{at}scilifelab.se

Data Availability

All available data included in the supplementary datasets

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 04, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease
Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Simon Lam, Hong Yang, Ebru Coskun, Ezgi İdil, Rahim Nogaylar, Ahmet Hacımuftuoglu, Muhammad Arif, Saeed Shoaie, Cheng Zhang, Jens Nielsen, Hasan Turkez, Jan Borén, Mathias Uhlén, Adil Mardinoglu
medRxiv 2021.07.28.21261293; doi: https://doi.org/10.1101/2021.07.28.21261293
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson’s Disease
Burak Yulug, Ozlem Altay, Xiangyu Li, Lutfu Hanoglu, Seyda Cankaya, Simon Lam, Hong Yang, Ebru Coskun, Ezgi İdil, Rahim Nogaylar, Ahmet Hacımuftuoglu, Muhammad Arif, Saeed Shoaie, Cheng Zhang, Jens Nielsen, Hasan Turkez, Jan Borén, Mathias Uhlén, Adil Mardinoglu
medRxiv 2021.07.28.21261293; doi: https://doi.org/10.1101/2021.07.28.21261293

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1097)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (502)
  • Epidemiology (9773)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2313)
  • Geriatric Medicine (223)
  • Health Economics (462)
  • Health Informatics (1562)
  • Health Policy (736)
  • Health Systems and Quality Improvement (604)
  • Hematology (238)
  • HIV/AIDS (504)
  • Infectious Diseases (except HIV/AIDS) (11650)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (238)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2144)
  • Nursing (134)
  • Nutrition (337)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (518)
  • Oncology (1180)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (147)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2182)
  • Public and Global Health (4663)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (624)
  • Rheumatology (274)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (210)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)